Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

John H. Stone, Janet T. Holbrook, Matthew A. Marriott, Andrea K. Tibbs, Lourdes P. Sejismundo, Y. I. Min, Ulrich Specks, Peter A. Merkel, Robert Spiera, John C. Davis, E. William St.Clair, W. Joseph McCune, Steven R Ytterberg, Nancy B. Allen, Gary S. Hoffman

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Objective. Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients. Methods. One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. Results. All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age- and sex-specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment. Conclusion. Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.

Original languageEnglish (US)
Pages (from-to)1608-1618
Number of pages11
JournalArthritis and Rheumatism
Volume54
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Granulomatosis with Polyangiitis
Cyclophosphamide
Neoplasms
Tumor Necrosis Factor-alpha
Therapeutics
Etanercept
Placebos
Remission Induction
Mucinous Adenocarcinoma
Liposarcoma
Sex Distribution
Cholangiocarcinoma
Tobacco Use
Random Allocation
Renal Cell Carcinoma
Colon
History
Maintenance
Alcohols
Breast Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Stone, J. H., Holbrook, J. T., Marriott, M. A., Tibbs, A. K., Sejismundo, L. P., Min, Y. I., ... Hoffman, G. S. (2006). Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism, 54(5), 1608-1618. https://doi.org/10.1002/art.21869

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. / Stone, John H.; Holbrook, Janet T.; Marriott, Matthew A.; Tibbs, Andrea K.; Sejismundo, Lourdes P.; Min, Y. I.; Specks, Ulrich; Merkel, Peter A.; Spiera, Robert; Davis, John C.; St.Clair, E. William; McCune, W. Joseph; Ytterberg, Steven R; Allen, Nancy B.; Hoffman, Gary S.

In: Arthritis and Rheumatism, Vol. 54, No. 5, 05.2006, p. 1608-1618.

Research output: Contribution to journalArticle

Stone, JH, Holbrook, JT, Marriott, MA, Tibbs, AK, Sejismundo, LP, Min, YI, Specks, U, Merkel, PA, Spiera, R, Davis, JC, St.Clair, EW, McCune, WJ, Ytterberg, SR, Allen, NB & Hoffman, GS 2006, 'Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial', Arthritis and Rheumatism, vol. 54, no. 5, pp. 1608-1618. https://doi.org/10.1002/art.21869
Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism. 2006 May;54(5):1608-1618. https://doi.org/10.1002/art.21869
Stone, John H. ; Holbrook, Janet T. ; Marriott, Matthew A. ; Tibbs, Andrea K. ; Sejismundo, Lourdes P. ; Min, Y. I. ; Specks, Ulrich ; Merkel, Peter A. ; Spiera, Robert ; Davis, John C. ; St.Clair, E. William ; McCune, W. Joseph ; Ytterberg, Steven R ; Allen, Nancy B. ; Hoffman, Gary S. / Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. In: Arthritis and Rheumatism. 2006 ; Vol. 54, No. 5. pp. 1608-1618.
@article{dd25acecc8234e5db4a7f26ee1d20bd4,
title = "Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial",
abstract = "Objective. Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients. Methods. One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. Results. All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age- and sex-specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment. Conclusion. Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.",
author = "Stone, {John H.} and Holbrook, {Janet T.} and Marriott, {Matthew A.} and Tibbs, {Andrea K.} and Sejismundo, {Lourdes P.} and Min, {Y. I.} and Ulrich Specks and Merkel, {Peter A.} and Robert Spiera and Davis, {John C.} and St.Clair, {E. William} and McCune, {W. Joseph} and Ytterberg, {Steven R} and Allen, {Nancy B.} and Hoffman, {Gary S.}",
year = "2006",
month = "5",
doi = "10.1002/art.21869",
language = "English (US)",
volume = "54",
pages = "1608--1618",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

AU - Stone, John H.

AU - Holbrook, Janet T.

AU - Marriott, Matthew A.

AU - Tibbs, Andrea K.

AU - Sejismundo, Lourdes P.

AU - Min, Y. I.

AU - Specks, Ulrich

AU - Merkel, Peter A.

AU - Spiera, Robert

AU - Davis, John C.

AU - St.Clair, E. William

AU - McCune, W. Joseph

AU - Ytterberg, Steven R

AU - Allen, Nancy B.

AU - Hoffman, Gary S.

PY - 2006/5

Y1 - 2006/5

N2 - Objective. Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients. Methods. One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. Results. All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age- and sex-specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment. Conclusion. Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.

AB - Objective. Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo-controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients. Methods. One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively. Results. All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age- and sex-specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept-treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment. Conclusion. Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.

UR - http://www.scopus.com/inward/record.url?scp=33646477546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646477546&partnerID=8YFLogxK

U2 - 10.1002/art.21869

DO - 10.1002/art.21869

M3 - Article

C2 - 16646004

AN - SCOPUS:33646477546

VL - 54

SP - 1608

EP - 1618

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -